{"name":"Point Therapeutics","slug":"point-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPalMxVGxMRUV5U0lmbWJGZWlqNnRPSGpMdThCVXFnaFF2RHl0Nmp3QW84c1dsSXZSTW41NUdfa0VuQXNhanpOcU5Qcm1jT2tTa0ppV3M4VFpVN3V6TVpwQzBKOXg3R3JPb3FxYmdEQ3l3RDhaMkwybVVTQmsyaUVTZ2NBRmhZRXE0d3B4NGxsWQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Yahoo Finance","summary":"Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns - Yahoo Finance","headline":"Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZWRRUXpyb1QxQ3h4dTBsaFpsNjM3aU9PM3RBMU9ZQ21namV4OEtENWZKSlhTSVZwZkFEUmJJaXFVdTh0YUs3V0s1NDN1Zk1wTG1iLXN6R3YtRWk0UWRqbE5wajBHcHFmMmZQYXBxeVNLUzJvbWpITlRyNDV2Z2t6QTlSc24xeWU2VzE0RDZOUFJGTmk2Qlh3?oc=5","date":"2026-01-20","type":"pipeline","source":"Yahoo Finance","summary":"Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance","headline":"Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-14","type":"earnings","source":"simplywall.st","summary":"Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st","headline":"Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPMEgzSk9RSUNyTEFvY0xCSEw0dkZtYjctUHhJaldJdGhUUU5LVHQwWk4tZFdVNnpLNUlaYlFwdFgtQkN3dWQ3UklwRVByaWJzSXdCQlIyM2dfV2gzSWwwVkN4RDFhaElIWHJ2eW1FQ3dqUVBtUEVxTHNYZ0QyX2ZIcm14N2FIdmRkTk1lV2E2aEJhZHJOSHk1a3NCUWN5UVZ2?oc=5","date":"2025-11-05","type":"pipeline","source":"C&EN","summary":"Inflection Point: How underappreciated critters inspired GLP-1 drugs - C&EN","headline":"Inflection Point: How underappreciated critters inspired GLP-1 drugs - C&EN","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-05","type":"earnings","source":"simplywall.st","summary":"Madrigal Pharmaceuticals (MDGL): Forecasts Point to 34.8% Annual Revenue Growth Ahead of Earnings - simplywall.st","headline":"Madrigal Pharmaceuticals (MDGL): Forecasts Point to 34.8% Annual Revenue Growth Ahead of Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQVGRyTzZGdU5wX1pGV2RPanZCa2s2ZjhhSTU1c2hMYkszVGNxdFItVVZRY19HUy02ZlpaVlRmWC15eWc4ek5XQnotYmNZN2ZqcV9kaUVIbWZvSXd0UDFERGsxM3l1LUxseXJwNHQ3T2EzUUlILVRsbDJBd0xoTnhac2lXWVZYaFUwSDJ3bXNaSkNCMmtrWHFEbFFQdmxoRWZQcTJTZDluZ3dJSW5FNFJz?oc=5","date":"2025-10-30","type":"pipeline","source":"The Business Journals","summary":"Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus - The Business Journals","headline":"Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNaC0zVlA3cnJJaVlTS0xINXBKUENVTWN1YW9zYXpITUQ1OXB6WjZUZjE4dmNFUEVKQ19rMW5WQldtMEVDNHZ5TXFjOW9sT3h1cU01QlVJaTJHSENKRTVvdUw2WkJWclR5eEVuRHRaOUdqRHlZYWNFSmxkYlMzOTA5TXpsbVNIYVIyeGVJ?oc=5","date":"2025-10-27","type":"pipeline","source":"Fierce Pharma","summary":"Are We Nearing a Tipping Point in Alzheimer’s Disease? - Fierce Pharma","headline":"Are We Nearing a Tipping Point in Alzheimer’s Disease?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQLThTNklCWDBaY1RnNHFnQ25RRkF3TVExX1E0NUwyNFNPc1NKV1lxT1JxSzQ4TmFJV0w2R053M2lrUmFLRTR3N0poQ1kxZVpuVGY3NTZxRmhmbXNuYms4bzZVR0R4UmhrTHhWOVlrY2U0YlZTX1JvaVBIa0h4Zm4yNWE2bEVPaWkwdXhUcDFvZWdrcHc2OXkxR1dBZFZBYjYxSDZHemt1TERHbk5fUmtaUFc3VFM4ZWM3bGgyaFNJVl9sZW13NmpEVS1LNmJUdDIxYlFNZGNDZmNBYkJQVVFTSg?oc=5","date":"2025-10-10","type":"deal","source":"Reuters","summary":"Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters","headline":"Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOdnc2MDRiTHk0NnU0NzBpdWZLalRYQWJoU1BaLWYtay1BVmpOQkxLTFQ0TERIaDVsa2FWTHctRnpuS1RDc1lYeFhkVXBUQTlDWHMzY2FTT3NmSEVkejNoQTlyY2R5aG1zdUIwbkZPUDdaV3AyV0RGekRuTXJCalhxSko1aWMzSE00Z184UEdLd2tZTlNnaFhHd2MyRjBpdEdjWXhETDZtSHA?oc=5","date":"2023-12-27","type":"pipeline","source":"Eli Lilly","summary":"Lilly Completes Acquisition of POINT Biopharma - Eli Lilly","headline":"Lilly Completes Acquisition of POINT Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUUZoUjFpLTdkWXZVMk9sOFdlRjFfMWdqMXFZU082amNKbmQ2Y2loTlNoUXIteWpuOFFQdzVLckJmYlV6Yjh4dHVhd1pDbV96N3UwVVFyaDdhaHVfSUdTaGtYOS1tZ2JIOTdUMTBZWlI1WVVvM0l3cVl0SVRQeWF0YUxaZDBnZk52RGdKQjlvSEZfN1VjeHpKX1llTQ?oc=5","date":"2023-12-18","type":"trial","source":"BioPharma Dive","summary":"Point radiopharma drug results disappoint in prostate cancer study - BioPharma Dive","headline":"Point radiopharma drug results disappoint in prostate cancer study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNdXJRcUc1Q1U4TVVSeW1UOFd5b2tneDVNX3VhaTFTcE1fZnQxUi1KT1Fwb0E1Q0Jwa3Njb2RRY1BwenV5cUpkWm1Ia2xrOFpsT3ZQenFuU3oyZjBoeWxKOEV5RUNaLUZtTVdiaGxEeS1DTUFYZ2NnekJnWkFiaTJuRHFRTy1WdzNYWVhkaTBpSWRlZVN1dXBkZnlPa0hFakZmQl9OdzQ4LW9OUThLSC10THg3ZXBHN1NBaWJuOHFYdnhwN2lzZldSRy0wOC1aN0VkejVweWhTVlVBZXRuaFFGaVVma2Y1ZzBUUTRrdTJIcU9ubVhJZUE?oc=5","date":"2023-10-03","type":"deal","source":"prnewswire.com","summary":"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies - prnewswire.com","headline":"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOa2FyTFRiaFVtRXZKdmJOWDNhVU9IcDI1b0d4bkotcFBpQ1otSjZWamdMVkxzVGdyY05mU2ZZVWg4cG1DR184clFVNS02eTBIbHFXREdVVzZUMFJrTmtCOXVNLTY0M3ZTR28tUnlkWGJ1QWE1NWhzaU4wS3lrOWZzMk43a0ktWDlhOHlIa1hKRk9JdTVfTjZLTXpPZUNGSzRWd3J2Nk1fX3lfV2hw?oc=5","date":"2023-10-03","type":"pipeline","source":"statnews.com","summary":"Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion - statnews.com","headline":"Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}